Back to Search
Start Over
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
- Source :
-
American Journal of Medicine . Feb2017, Vol. 130 Issue 2, p229.e1-229.e4. 1p. - Publication Year :
- 2017
-
Abstract
- Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density lipoprotein. The fact the agent is a monoclonal antibody has led to limited drug interactions and minimized adverse drug events. It is critical for all providers to have a basic understanding of these novel therapies with their introduction and use for treatment. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00029343
- Volume :
- 130
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- American Journal of Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 120889467
- Full Text :
- https://doi.org/10.1016/j.amjmed.2016.09.021